Sugi Predict

Sugi Predict / Compounds / SCHEMBL1764933

SCHEMBL1764933

SCHEMBL1764933

OC1(c2ccccc2)CCCNC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.50
▸ OPRM1 P35372 3/20 0.44
▸ OPRL1 P41146 3/20 0.42
▸ OPRK1 P41145 2/20 0.42
▸ CYP2D6 P10635 4/20 0.41
▸ CYP3A4 P08684 3/20 0.41
▸ USP2 O75604 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ DRD2 P14416 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ SIGMAR1 Q99720 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15093618 1.00 HTR2A (0.50) HTR2AOPRM1OPRL1OPRK1CYP2D6
SCHEMBL15093858 1.00 HTR2A (0.50) HTR2AOPRM1OPRL1OPRK1CYP2D6
Bromide SCHEMBL7252604 0.98 HTR2A (0.48) HTR2AOPRM1OPRL1OPRK1CYP2D6
Hydrochloric Acid SCHEMBL10754178 0.98 HTR2A (0.48) HTR2AOPRM1OPRL1OPRK1CYP2D6
SCHEMBL15093670 0.88 HTR2A (0.59) HTR2AOPRM1OPRL1OPRK1DRD2
SCHEMBL1205790 0.88 HTR2A (0.59) HTR2AOPRM1OPRL1OPRK1DRD2
SCHEMBL15093944 0.88 HTR2A (0.59) HTR2AOPRM1OPRL1OPRK1DRD2
Hydrochloric Acid SCHEMBL3545524 0.86 HTR2A (0.57) HTR2AOPRM1OPRL1OPRK1DRD2
SCHEMBL16565576 0.85 DRD2 (0.56) HTR2AOPRM1OPRL1OPRK1CYP2D6
SCHEMBL21944503 0.81 DRD2 (0.41) HTR2AOPRM1OPRL1OPRK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122050-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN claimed
CN-109810047-A (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani 上海博邦医药科技有限公司 2019-05-28 — — CN claimed
CN-107207482-A Pyrimidine derivatives for treating cancer 默克专利股份公司 2017-09-26 — — CN claimed
US-7790898-B2 Substituted 3-phenylpiperidine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2010-09-07 — — US claimed
US-20070173533-A1 Substituted 3-phenylpiperidine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-07-26 — — US claimed
EP-0192522-B1 1-ETHYL- 3-HYDROXY-3-PHENYLPIPERIDINE, PROCESS FOR ITS PREPARATION AND ITS THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1988-08-31 — — EP claimed
EP-0192522-A1 1-ethyl- 3-hydroxy-3-phenylpiperidine, process for its preparation and its therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1986-08-27 — — EP claimed
CN-113122050-B Quantum dot ink and preparation method of quantum dot film TCL科技集团股份有限公司 2022-11-04 — — CN disclosed
CN-113122050-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN disclosed
US-20200325128-A1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER Argonaut Therapeutics Limited (GB) 2020-10-15 — — US disclosed
US-10428019-B2 Chiral auxiliaries WAVE LIFE SCIENCES LTD. (SG) 2019-10-01 — — US disclosed
US-10428019-B2 Chiral auxiliaries WAVE LIFE SCIENCES LTD. (SG) 2019-10-01 — — US disclosed
CN-109810047-A (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani 上海博邦医药科技有限公司 2019-05-28 — — CN disclosed
EP-0192521-A1 3-Phenyl-tetrahydropyridine derivatives, process for their preparation and their therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1986-08-27 — — EP disclosed
EP-0192522-A1 1-ethyl- 3-hydroxy-3-phenylpiperidine, process for its preparation and its therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1986-08-27 — — EP disclosed
EP-0192522-A1 1-ethyl- 3-hydroxy-3-phenylpiperidine, process for its preparation and its therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1986-08-27 — — EP disclosed
EP-0192522-A1 1-ethyl- 3-hydroxy-3-phenylpiperidine, process for its preparation and its therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1986-08-27 — — EP disclosed
US-4077958-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1978-03-07 — — US disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 — — US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428019-B2 Chiral auxiliaries PCNA, POLL, TYMP HTR2A 4300/4885OPRM1 2866/4885OPRL1 2433/4885
US-20200325128-A1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER PRMT5, PRMT6, PRMT1 HTR2A 4558/4885OPRM1 4536/4885OPRL1 4573/4885
US-20070173533-A1 Substituted 3-phenylpiperidine compounds, their preparation and use OPRK1, OPRD1, OPRL1 HTR2A 44/4885OPRM1 4/4885OPRL1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.